Next-generation metabolomics and AI technology supports the 2026 – 2035 Pan-Canadian Lung Cancer Action Plan’s

BioMark’s Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial Extensive Validation of

BioMark Secures Key Patents in Asia’s Largest Markets for Early Lung Cancer Liquid Biopsy Pioneering

BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership Proof-of-Concept Trial Opens Door

Press Release – BioMark Diagnostics Announces Expansion of its Specialty Laboratory Services in Quebec to

BioMark Diagnostics Highlights Fiscal Year 2025 Achievements and Sets Bold Strategic Milestones for 2025 –

Novel Graph Neural Network (N-GNN) Model Achieves Superior Accuracy in Early Lung Cancer Detection, Paving

Study Published in a special issue of International Journal of Molecular Sciences Confirms Test’s Ability

Milestone strengthens transparency and credibility as the Company advances commercialization of its metabolomics technology platform